RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with
advanced solid tumor malignancies who are intolerant of existing therapies known to
provide clinical benefit, have disease that has progressed after standard therapy, or
have previously failed other therapies. The study has two phases. The purpose of Phase 1a
(Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose
Expansion) is to characterize the safety and efficacy of RSC-1255.
Additional locations may be listed on ClinicalTrials.gov for NCT04678648.
Locations matching your search criteria
United States
California
Los Angeles
UCLA / Jonsson Comprehensive Cancer CenterStatus: Active
Contact: Rose Marie Estrada
Phone: 310-633-8400ext20276
RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS
inhibitor. RSC-101 is a Phase 1a/1b, open-label, multi-center, non-randomized, Dose
Escalation and Dose Expansion study in participants with advanced solid tumor
malignancies. Study enrollment is approximately 134 participants. All participants
receive oral RSC-1255, twice daily as monotherapy. Following Phase 1a (Dose Escalation)
to identify the Maximum Tolerated Dose and Recommended Dose for use in Phase 1b,
additional participants are enrolled in the Phase 1b (Dose Expansion) to further
characterize the safety, pharmacology, and the clinical efficacy of RSC-1255.
Lead OrganizationRasCal Therapeutics, Inc.
